
Geron (GERN) Stock Forecast & Price Target
Geron (GERN) Analyst Ratings
Bulls say
Geron is supported by a commercial story that is now anchored by RYTELO’s approved LR-MDS franchise, where management reported $57.5M of revenue in 2Q:26, 11% sequential growth, about 1,575 ordering accounts, and gross-to-net in the low 20% range. The 2026 IMpactMF discontinuation removes a potential myelofibrosis upside stream, but the lack of new safety signals and the belief that the control arm improved over time suggest the decision does not undermine imetelstat’s biology or RYTELO’s physician adoption. With NCCN preferred status in 1L and 2L settings, ongoing community expansion, $221M in estimated YE:26 net cash, and a high-probability MDS outlook, the fundamentals still justify a constructive view.
Bears say
Geron is facing a weaker fundamental outlook because the Phase 3 IMpactMF trial in JAK inhibitor-relapsed/refractory myelofibrosis was discontinued after the independent Data Monitoring Committee said it was unlikely to meet its primary overall survival endpoint, removing a major growth opportunity from the model. The setback matters because the myelofibrosis program had been a key source of upside beyond the approved RYTELO franchise, and the company’s own analysis now drops MF credit despite no new safety signals and an unchanged imetelstat safety profile. Although the smaller Phase 2 MYF2001 study showed encouraging median overall survival of 29.9 months versus about 12 months in a matched real-world cohort, the limited sample size and reliance on external comparison data make that evidence insufficient to offset the late-stage failure.
This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Geron (GERN) Forecast
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares